GlassScriptPhysician profile
Ariuka Arya
NPI 1427728070
$3,001.93
in general payments reported to CMS, 2019-2025
38 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $145 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,902.93 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $430.28 | 2025 | Talvey, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $334.95 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $235.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.20 | 2025 | Calquence, Lynparza, Imfinzi |
| Glaxosmithkline, LLC. | $138.37 | 2025 | Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $117.30 | 2024-2025 | |
| Abbvie INC. | $109.39 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $86.96 | 2025 | Libtayo |
| Daiichi Sankyo INC. | $86.06 | 2025 | Enhertu, Injectafer |
| Springworks Therapeutics, INC. | $75.75 | 2025 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $72.17 | 2025 | Fruzaqla |
| Genmab U.S., INC. | $68.77 | 2025 | Epkinly |
| Adc Therapeutics America, INC. | $68.15 | 2025 | |
| Pfizer INC. | $68.04 | 2025 | |
| Lilly USA, LLC | $63.48 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $63.24 | 2025 | Cresemba, Padcev |
| Sobi, INC | $61.50 | 2025 | |
| Genzyme Corporation | $57.43 | 2025 | |
| Eisai INC. | $56.00 | 2024-2025 | |
| Exelixis INC. | $55.19 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $51.93 | 2025 | Besremi |
| Puma Biotechnology, INC. | $51.35 | 2025 | Nerlynx |
| Array Biopharma INC | $49.57 | 2025 | Lorbrena, Mektovi, Braftovi |
| Genentech USA, INC. | $44.89 | 2025 | Tecentriq, Ocrevus Zunovo |
| Emd Serono, INC. | $42.63 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $38.49 | 2025 | Onivyde |
| Incyte Corporation | $36.01 | 2025 | Monjuvi, Zynyz, Jakafi |
| Gilead Sciences, INC. | $27.59 | 2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $27.26 | 2025 | Monoferric |
| Iovance Biotherapeutics, INC. | $27.17 | 2025 | Amtagvi |
| Invivyd INC | $23.64 | 2024 | Pemgarda |
| Servier Pharmaceuticals LLC | $20.61 | 2025 | |
| Tersera Therapeutics LLC | $20.06 | 2025 | Zoladex |
| Adaptive Biotechnologies Corporation | $17.11 | 2025 | Clonoseq |
| Spectrum Pharmaceuticals INC. | $16.84 | 2025 | Rolvedon |
| Azurity Pharmaceuticals, INC. | $15.84 | 2025 | Danziten |
| Tactile Systems Technology INC | $14.96 | 2025 | Nimbl, Flexitouch Plus |
| Deciphera Pharmaceuticals INC. | $14.76 | 2025 | Tgct, Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariuka Arya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.